Gut health hope: probiotic trial launches for Sjogren's
NCT ID NCT06297213
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial will test an oral probiotic called R-2487 in 36 adults with Sjogren's syndrome. The main goal is to see if the probiotic is safe and tolerable. Researchers will also check for changes in disease activity and inflammation using blood and stool samples. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- R-2487 (a probiotic taken by mouth)
- What this could lead to
- If this works, it could point toward a new way to manage Sjogren's syndrome by improving gut health and reducing inflammation.
- What could go wrong
- This is a very early Phase 1 trial with only 36 people, focused on safety. It is too soon to know if the probiotic will actually help symptoms, and it may not show any benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A swallowable spy pill could unlock Sjögren's secrets
- Experimental biologic CND319 takes first steps toward taming autoimmune diseases
- Study aims to sharpen Sjögren's diagnosis
- Are women with autoimmune diseases getting the gynecological care they need?
- Sjögren's syndrome study digs deep into Mind-Body connection
- New injection aims to tame stubborn autoimmune diseases